Myhibbin Side Effects

Generic name: mycophenolate mofetil

Medically reviewed by Drugs.com. Last updated on Jul 1, 2024.

Note: This document provides detailed information about Myhibbin Side Effects associated with mycophenolate mofetil. Some dosage forms listed on this page may not apply specifically to the brand name Myhibbin.

Applies to mycophenolate mofetil: intravenous powder for solution.

Other dosage forms:

• oral capsule, oral powder for suspension, oral tablet

Important warnings This medicine can cause some serious health issues

Intravenous route (powder for solution)

Embryofetal Toxicity, Malignancies and Serious Infections. Use during pregnancy is associated with increased risks of first trimester pregnancy loss and congenital malformations.

Avoid if safer treatment options are available.

Females of reproductive potential must be counseled regarding pregnancy prevention and planning.Increased risk of development of lymphoma and other malignancies, particularly of the skin.Increased susceptibility to infections, including opportunistic infections and severe infections with fatal outcomes.

Serious side effects of Myhibbin

Along with its needed effects, mycophenolate mofetil (the active ingredient contained in Myhibbin) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking mycophenolate mofetil:

More common side effects

• blood in the urine
• chest pain or discomfort
• cough or hoarseness
• difficulty in moving
• fever or chills
• increased cough
• loss of strength or energy
• lower back or side pain
• muscle pain, cramps, stiffness, or weakness
• pain in the joints
• painful or difficult urination
• swelling of the feet or lower legs
• trouble breathing

Less common side effects

• black, tarry stools
• bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, or warmth at injection site
• bloody vomit
• enlarged gums
• irregular heartbeat
• joint pain
• pinpoint red spots on the skin
• red, inflamed, or bleeding gums
• sores inside the mouth
• stomach pain
• trembling or shaking of the hands or feet
• unusual bleeding or bruising
• white patches on the mouth, tongue, or throat

Incidence not known

• back pain
• bloody, black, tarry stools
• blue lips, fingernails, or skin
• blurred vision
• chronic or occasional diarrhea
• clumsiness
• confusion
• coughing or spitting up blood
• difficulty speaking or understanding what others say
• dizziness
• drowsiness
• general feeling of illness or nausea
• headache
• heart murmur
• irregular, fast or slow, or shallow breathing
• loss of coordination
• memory loss
• night sweats
• seizures
• severe headache
• sore throat
• stiff neck or back
• stomach distention
• stools that float, are foul smelling, or "fatty"
• sudden high fever or low-grade fever for months
• unusual tiredness or weakness
• vision changes
• weakness in the legs

Other side effects of Myhibbin

Some side effects of mycophenolate mofetil may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common side effects

• constipation
• diarrhea
• heartburn
• nausea
• vomiting
• weakness

Less common side effects

• acne
• skin rash
• trouble sleeping

For healthcare professionals

Applies to mycophenolate mofetil: intravenous powder for injection, oral capsule, oral powder for reconstitution, oral tablet.

Gastrointestinal adverse events

• Very common (10% or more): Diarrhea (36%), nausea (20%), vomiting (13%), abdominal pain
• Common (1% to 10%): GI infection, gastroenteritis
• Rare (less than 0.1%): Gingival hyperplasia, colitis including cytomegalovirus colitis, pancreatitis intestinal villous atrophy
• Frequency not reported: Ischaemic colitis^[Ref]

Hematologic

• Very common (10% or more): Leukopenia (11% to 35%), anemia (35%)
• Common (1% to 10%): Blood creatinine increased, blood lactate dehydrogenase increased, blood urea increased, blood alkaline phosphatase increased, thrombocytopenia, neutropenia
• Very rare (less than 0.01%): Deep venous thrombosis
• Postmarketing reports: Pure red cell aplasia (PRCA), abnormal neutrophil morphology, including the acquired Pelger-Huet anomaly, bone marrow failure, lymphocele^[Ref]

Immunologic

• Very common (10% or more): Sepsis (primarily cytomegalovirus viremia) (20%), gastrointestinal candidiasis, urinary tract infection, herpes simplex, herpes zoster
• Common (1% to 10%): Pneumonia, influenza, respiratory tract infection, respiratory moniliasis, gastrointestinal infection, candidiasis, gastroenteritis, infection, bronchitis, pharyngitis, sinusitis, fungal skin infection, skin candida, vaginal candidiasis
• Postmarketing reports: Hypogammaglobulinemia, hypersensitivity, and serious life-threatening infections including meningitis, endocarditis, tuberculosis, atypical mycobacterial infection^[Ref]

Oncologic

• Common (1% to 10%): Lymphoma, lymphoproliferative disease, non-melanoma skin carcinoma
• Uncommon (0.1% to 1%): Post-transplant lymphoproliferative disease (pseudolymphoma)^[Ref]

Renal

• Very common (10% or more): Hematuria (13%), kidney tubular necrosis (up to 10%)
• Common (1% to 10%): Renal impairment
• Frequency not reported: BK virus-associated nephropathy^[Ref]

Metabolic

• Very common (10% or more): Edema (12% to 28%), hyperphosphatemia (13%), hypokalemia (10%), hyperglycaemia (10%)
• Common (1% to 10%): Weight loss, hyperkalemia^[Ref]

Respiratory

• Very common (10% or more): Respiratory tract infection (23%), dyspnea (16%), increased cough (16%)
• Common (1% to 10%): Pneumonia, respiratory moniliasis, bronchitis, pharyngitis, sinusitis, rhinitis, pleural effusion
• Postmarketing reports: Bronchiectasis, interstitial lung disease, fatal pulmonary fibrosis^[Ref]

Dermatologic

• Common (1% to 10%): Fungal skin infection, skin hypertrophy, rash, acne, alopecia
• Very rare (less than 0.01%): Dyshidrotic eczema, papulosquamous psoriatic-like skin eruption^[Ref]

Other

• Common (1% to 10%): Edema, pyrexia, chills, pain, malaise, asthenia
• Frequency not reported: Congenital malformations, increased incidence of first trimester pregnancy loss^[Ref]

Musculoskeletal

• Common (1% to 10%): Arthralgia
• Very rare (less than 0.01%): Myopathy^[Ref]

Hepatic

• Common (1% to 10%): Hepatitis, jaundice, hyperbilirubinemia, hepatic enzyme increased
• Very rare (less than 0.01%): Sodium-induced hepatotoxicity^[Ref]

Cardiovascular

• Common (1% to 10%): Tachycardia, hypotension, hypertension, vasodilatation
• Postmarketing reports: Endocarditis, venous thrombosis^[Ref]

Genitourinary

• Common (1% to 10%): Urinary tract infection (up to 45%), vaginal candidiasis^[Ref]

Hypersensitivity

• Postmarketing reports: Angioneurotic edema, anaphylactic reaction^[Ref]

Further information

Myhibbin side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.

Medical Disclaimer